Open Peer Review on Qeios

Zalifrelimab

National Cancer Institute

Source

National Cancer Institute. Zalifrelimab. NCI Thesaurus. Code C126113.

A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CT LA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CT LA-4 expressed on T-cells and inhibits the CT LA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CT L)-mediated immune response against cancer cells. CT LA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.